• endocrine therapy
• androgen deprivation therapy (ADT)
• abiraterone plus ADT
• abiraterone plus docetaxel plus ADT
• apalutamide plus ADT
• darolutamide plus doxetaxel plus ADT
• docetaxel plus ADT
• enzalutamide
• enzalutamide plus ADT
• immune chekpoint inhibitors
• anti-CTLA-4
• ipilimumab based treatment
• ipilimumab alone
• anti-PD-(L)1
• pembrolizumab based treatment

• versus all
• vs chemotherapy
• vs Standard of Care (SoC)
• vs endocrine therapy
• vs androgen deprivation therapy (ADT)
• vs docetaxel plus ADT
• vs enzalutamide
• vs immune chekpoint inhibitors
• vs anti-CTLA-4
• vs ipilimumab based treatment
• vs ipilimumab alone
• vs Ipilimumab (10 mg/kg)
• vs non active control
• vs placebo

  Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

color = results color = ROB demonstrated suggested inconclusive safety concern ongoing study not assessable low moderate serious ongoing study display ongoing demontrated benefit only